1. Articles in category: Disease Classification

    1-24 of 179 1 2 3 4 5 6 7 8 »
    1. Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Cell Tissue Res. 2018 Mar 23;:

      Authors: Tolbert VP, Matthay KK

      Abstract Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life.

      Read Full Article
      Mentions: Treatment MYCN
    2. Epigenetic analysis: Giving the right name to a tumor

      Epigenetic analysis: Giving the right name to a tumor

      ( Heidelberg University Hospital and Medical Faculty ) Scientists from the 'Hopp Children's Cancer Center at the NCT Heidelberg' (KiTZ) and the Neuropathology Department at Heidelberg University Hospital have substantially enhanced the classification of tumors of the central nervous system (CNS) / Physicians will now be able to categorize CNS tumors more precisely into specific risk groups and make therapy decisions on this basis / The method was developed in close collaboration with the German Cancer Consortium (DKTK) / Publication in Nature.

      Read Full Article
    3. Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Radiographics. 2018 Mar-Apr;38(2):566-580

      Authors: Swift CC, Eklund MJ, Kraveka JM, Alazraki AL

      Abstract Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. It is the most common extracranial solid tumor of childhood and accounts for up to 15% of all pediatric cancer fatalities.

      Read Full Article
      Mentions: Treatment
    4. Cross-cohort analysis identifies a TEAD4 ↔ Mycn positive-feedback loop as the core regulatory element of high-risk neuroblastoma.

      Cross-cohort analysis identifies a TEAD4 ↔ MYCN positive-feedback loop as the core regulatory element of high-risk neuroblastoma.

      Cancer Discov. 2018 Mar 06;:

      Authors: Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, Koster J, Asgharzadeh S, Seeger RC, Wei JS, Khan J, Vandesompele J, Mestdagh P, Versteeg R, Look AT, Young RA, Iavarone A, Lasorella A, Silva JM, Maris JM, Califano A

      Abstract High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, the molecular ...

      Read Full Article
      Mentions: MYCN
    5. Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Exp Cell Res. 2018 Feb 27;:

      Authors: Xu DQ, Toyoda H, Yuan XJ, Qi L, Chelakkot VS, Morimoto M, Hanaki R, Kihira K, Hori H, Komada Y, Hirayama M

      Abstract Neuroblastoma (NB) is one of the most common solid tumors in children. High-risk NB remains lethal in about 50% of patients despite comprehensive and intensive treatments.

      Read Full Article
    6. Association between NEFL Gene Polymorphisms and Neuroblastoma Risk in Chinese Children: A Two-Center Case-Control Study.

      Association between NEFL Gene Polymorphisms and Neuroblastoma Risk in Chinese Children: A Two-Center Case-Control Study.

      J Cancer. 2018;9(3):535-539

      Authors: Wu Q, Zhuo ZJ, Zeng J, Zhang J, Zhu J, Zou Y, Zhang R, Yang T, Zhu D, He J, Xia H

      Abstract Neuroblastoma is a lethal tumor that mainly occurs in children. To date, the genetic etiology of sporadic neuroblastoma remains obscure.

      Read Full Article
    7. Molecular mechanisms and therapeutic targets in neuroblastoma.

      Molecular mechanisms and therapeutic targets in neuroblastoma.

      Pharmacol Res. 2018 Feb 18;:

      Authors: Johnsen JI, Dyberg C, Fransson S, Wickström M

      Abstract Neuroblastoma is the most common extracranical tumor of childhood and the most deadly tumor of infancy. It is characterized by early age onset and high frequencies of metastatic disease but also the capacity to spontaneously regress.

      Read Full Article
    8. Dose-escalation is needed for gross disease in high-risk neuroblastoma

      Locoregional failure is common after subtotal resection in high-risk neuroblastoma. Although a dose of 21 Gy radiation therapy (RT) is standard for treatment of high-risk neuroblastoma after gross total resection, the dose needed for local control of patients with gross residual disease at the time of RT is unknown. We sought to evaluate local control after 21–36 Gy RT in patients with high-risk neuroblastoma undergoing subtotal resection.

      Read Full Article
      Mentions: Treatment
    9. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

      Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

      PLoS Med. 2018 Feb;15(2):e1002505

      Authors: Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J

      Read Full Article
    10. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    11. Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

      Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

      Int J Radiat Oncol Biol Phys. 2018 Jan 09;:

      Authors: Casey DL, Pitter KL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL

      Read Full Article
    12. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2304-2319

      Authors: Arnhold V, Schmelz K, Proba J, Winkler A, Wünschel J, Toedling J, Deubzer HE, Künkele A, Eggert A, Schulte JH, Hundsdoerfer P

      Read Full Article
      Mentions: MYCN
    13. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site.

      Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site.

      Q J Nucl Med Mol Imaging. 2018 Feb 05;:

      Authors: Gauthé M, Breton M, Jehanno N, Cellier C, Michon J, Sarnacki S, Schleiermacher G, Wartski M

      Read Full Article
      Mentions: Surgery Imaging MYCN
    14. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

      MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

      Biochim Biophys Acta. 2018 Feb 02;:

      Authors: Ferrucci F, Ciaccio R, Monticelli S, Pigini P, di Giacomo S, Purgato S, Erriquez D, Bernardoni R, Norris M, Haber M, Milazzo G, Perini G

      Read Full Article
      Mentions: MYCN
    15. SPECT/CT Mibg Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma.

      SPECT/CT MIBG Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma.

      Clin Nucl Med. 2018 Feb 03;:

      Authors: Liu B, Servaes S, Zhuang H

      Abstract BACKGROUND: Planar whole-body imaging with I-radiolabeled metaiodobenzylguanidine (I-MIBG) is routinely used in the follow-up evaluation of neuroblastoma. In recent years, SPECT with integrated low-dose CT (SPECT/CT) has become more accessible.

      Read Full Article
      Mentions: Imaging MIBG
    16. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      Lancet Child Adolesc Health. 2018 Jan;2(1):25-34

      Authors: de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL

      Read Full Article
      Mentions: COG Chemotherapy
    17. Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents.

      Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents.

      Pediatr Blood Cancer. 2018 Jan 25;:

      Authors: Alexander N, Sullivan K, Shaikh F, Irwin MS

      Abstract BACKGROUND: Ganglioneuromas (GNs) usually demonstrate favorable histological and clinical features.

      Read Full Article
      Mentions: Surgery
    18. Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents

      Ganglioneuromas (GNs) usually demonstrate favorable histological and clinical features. Surgery is often performed due to clinical symptoms and/or theoretical concerns that GN may transform into neuroblastoma (NB); however, several studies have identified significant GN-surgical morbidities.

      We compared the natural history, biological and clinical features of GN and ganglioneuroblastoma-intermixed (GNB-I) managed by surgery or observation to inform management and surveillance.

      Read Full Article
      Mentions: Surgery
    19. 'Hijacker' drives cancer in some patients with high-risk neuroblastoma

      Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including ...

      Read Full Article
    20. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma

      The New Approaches to Neuroblastoma Therapy Response Criteria (NANTRC) were developed to optimize response assessment in patients with recurrent/refractory neuroblastoma. Response predictors and associations of the NANTRC version 1.0 (NANTRCv1.0) and prognostic factors with outcome were analyzed.

      Read Full Article
      Mentions: Refractory NANT MYCN
    21. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      Invest New Drugs. 2016 Dec;34(6):685-692

      Authors: Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE

      Abstract Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes.

      Read Full Article
      Mentions: Treatment Relapse
    22. Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

      Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

      Oncotarget. 2017 Dec 08;8(64):107513-107529

      Authors: Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J

      Read Full Article
      Mentions: ALK MYCN
    1-24 of 179 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles